Hospitalization for respiratory syncytial virus illness in down syndrome following prophylaxis with palivizumab

Pediatric Infectious Disease Journal

Volumn 33, Issue 2, 2014, Pages

  Paes, Bosco ^a   Mitchell, Ian ^b   Yi, Hao ^c   Li, Abby ^c   Lanctôt, Krista L ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Down syndrome; outcomes; palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; ASSISTED VENTILATION; BIRTH WEIGHT; CAUCASIAN; CHEMOPROPHYLAXIS; CHILD; CONTROLLED STUDY; DAY CARE; DOWN SYNDROME; FEMALE; GENDER; GESTATIONAL AGE; HOSPITALIZATION; HOUSEHOLD; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MATERNAL SMOKING; MULTIPLE PREGNANCY; OXYGEN THERAPY; PATIENT COMPLIANCE; PNEUMOVIRUS INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RISK FACTOR; SEASONAL VARIATION; SEPSIS; SIBLING; SMOKING;

ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CANADA; DOWN SYNDROME; FEMALE; HOSPITALIZATION; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TREATMENT OUTCOME;

EID: 84892983262     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000019     Document Type: Article

References (30)

1. Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome a novel risk factor for respiratory syncytial virus bronchiolitis-a prospective birth-cohort study. Pediatrics. 2007;120e1076-e1081
2. Medrano C, Garcia-Guereta L, Grueso J, et al.; CIVIC Study Group from the Spanish Society of Pediatric Cardiology and Congenital Heart Disease. Respiratory infection in congenital cardiac disease. Hospitalizations in young children in Spain during 2004 and 2005 the CIVIC Epidemiologic Study. Cardiol Young. 2007;17360-371
3. Uong EC, McDonough JM, Tayag-Kier CE, et al. Magnetic resonance imaging of the upper airway in children with Down syndrome. Am J Respir Crit Care Med. 2001;163(3 pt 1)731-736
4. Cooney TP, Thurlbeck WM. Pulmonary hypoplasia in Down's syndrome. N Engl J Med. 1982;3071170-1173
5. Cooney TP, Wentworth PJ, Thurlbeck WM. Diminished radial count is found only postnatally in Down's syndrome. Pediatr Pulmonol. 1988;5204-209
6. Macchini F, Leva E, Torricelli M, et al. Treating acid reflux disease in patients with Down syndrome pharmacological and physiological approaches. Clin Exp Gastroenterol. 2011;419-22
7. Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011;1649-16
8. Bloemers BL, van Bleek GM, Kimpen JL, et al. Distinct abnormalities in the innate immune system of children with Down syndrome. J Pediatr. 2010;156804-9, 809.e1
9. Bloemers BL, Broers CJ, Bont L, et al. Increased risk of respiratory tract infections in children with Down syndrome the consequence of an altered immune system. Microbes Infect. 2010;12799-808
10. Bloemers BL, Bont L, de Weger RA, et al. Decreased thymic output accounts for decreased naive T cell numbers in children with Down syndrome. J Immunol. 2011;1864500-4507
11. de Hingh YC, van der Vossen PW, Gemen EF, et al. Intrinsic abnormalities of lymphocyte counts in children with down syndrome. J Pediatr. 2005;147744-747
12. Gemen EF, Verstegen RH, Leuvenink J, et al. Increased circulating apoptotic lymphocytes in children with Down syndrome. Pediatr Blood Cancer. 2012;591310-1312
13. Kristensen K, Stensballe LG, Bjerre J, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child. 2009;94785-789
14. Zachariah P, Ruttenber M, Simões EA. Down syndrome and hospitalizations due to respiratory syncytial virus a population-based study. J Pediatr. 2012;160827-31.e1
15. Kristensen K, Hjuler T, Ravn H, et al. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization a population-based cohort study. Clin Infect Dis. 2012;54810-817
16. Robinson J. Preventing respiratory syncytial virus infections. Paediatr Child Health. 2011;16487-490
17. Committee on Infectious Diseases. From the American Academy of Pediatrics Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pedatrics. 2009;1241694-1701
18. Frogel M, Nerwen C, Cohen A, et al.; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28511-517
19. Robinson KA, Saldanha IJ, McKoy NA. Management of infants with cystic fibrosis a summary of the evidence for the cystic fibrosis foundation working group on care of infants with cystic fibrosis. J Pediatr. 2009;155(6suppl)S94- S105
20. Paes B, Manzoni P. Special populations do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis Early Hum Dev. 2011;87 (suppl 1)S55-S58
21. Mitchell I, Paes BA, Li A, et al.; CARESS investigators. CARESS the Canadian registry of palivizumab. Pediatr Infect Dis J. 2011;30651-655
22. Chaney RH, Eyman RK, Miller CR. The relationship of congenital heart disease and respiratory infection mortality in patients with Down's syndrome. J Ment Defic Res. 1985;29 (pt 1)23-27
23. Hilton JM, Fitzgerald DA, Cooper DM. Respiratory morbidity of hospitalized children with Trisomy 21. J Paediatr Child Health. 1999;35383-386
24. Medrano López C, García-Guereta Silva L, Lirio Casero J, et al.; Grupo CIVIC, Grupo de Trabajo de Infecciones de la Sociedad Española de Cardiología Pediátrica y Cardiopatías Congénitas. [Respiratory infections, Down's syndrome and congenital heart disease the CIVIC 21 study].An Pediatr (Barc). 2009;7138-46
25. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137865-870
26. Schanzer DL, Langley JM, Tam TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J. 2006;25795-800
27. Megged O, Schlesinger Y. Down syndrome and respiratory syncytial virus infection. Pediatr Infect Dis J. 2010;29672-673
28. Government of Ontario, Health and Long-Term Care. Respiratory syncytial virus (rsv) prophylaxis for high risk infants program enrolment (014-4645-87E). 2013. Available at httpwww.forms.ssb.gov.on.cambsssbforms ssbforms. nsfAttachDownloadopenagent&TM=1115201321237PM&ENV=WWE&NO= 014-4645-87E&SEQ=1&VER=7. Accessed November 15, 2013
29. Feltes TF, Cabalka AK, Meissner HC, et al.; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143532-540
30. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102531-537